肌层浸润性膀胱癌女性新辅助化疗后妇科器官受累的当代发生率
该回顾性研究纳入2005至2018年186例cT2-T3肌层浸润性膀胱癌女性,67.7%接受新辅助化疗。妇科器官受累仅5.7%,且新辅助化疗组与未化疗组无差异;复发或转移率两组相似。即使高危患者,妇科器官受累罕见,保留卵巢等器官可能安全。
要点
- 肌层浸润性膀胱癌女性妇科器官受累率低(5.7%)。
- 新辅助化疗未显著改变妇科器官受累率。
- 保留卵巢等妇科器官可能安全。
核心结论
- 即使高危肌层浸润性膀胱癌女性,妇科器官受累罕见,保留卵巢等器官可能安全。
研究设计与样本
- 单中心回顾性审查2005至2018年186例cT2-T3肌层浸润性膀胱癌女性根治性膀胱切除术患者,按是否接受新辅助化疗分层。
主要发现
- 新辅助化疗组更常见cT3疾病、术前肾积水和变异组织学(p<0.001,p=0.004,p=0.029)。
- 两组复发或转移率相似(27.0% vs 26.7%,p=0.964),无孤立泌尿生殖器官复发(中位随访32.1个月)。
- 9例(5.7%)妇科器官受累(新辅助化疗组6例 vs 未化疗组3例,p=0.978)。
- 接受子宫切除术者中新辅助化疗组2例(3.1%)子宫受累,未化疗组无(p=0.551);阴道受累率两组相似(4例 vs 3例,p=0.402)。
- 1例新辅助化疗患者偶然诊断局限性子宫内膜癌;无输卵管或卵巢受累。
临床怎么用
- 根据美国泌尿外科学会/美国临床肿瘤学会/美国放射肿瘤学会/泌尿肿瘤学会指南,女性肌层浸润性膀胱癌根治性膀胱切除术应行前盆腔脏器切除术,但本研究支持妇科器官受累率低,保留卵巢等器官可能安全。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: According to the American Urological Association/American Society of Clinical Oncology/American Society for Radiation Oncology/Society of Urologic Oncology Guideline on treatment of nonmetastatic muscle invasive bladder cancer (MIBC), females requiring radical cystectomy (RC) should undergo concomitant anterior pelvic exenteration despite low rates of malignant involvement of gynecologic organs. We present the clinicopathological characteristics of patients with MIBC treated with neoadjuvant chemotherapy (NAC) and evaluate the impact of NAC on gynecologic organ involvement. MATERIALS AND METHODS: An institutional review board approved review of patients with cT2-T3 MIBC treated with RC at our institution between 2005 and 2018 was performed. Patients were stratified by receipt of NAC. RESULTS: A total of 186 females with cT2-T3 MIBC underwent RC during the study period, of whom 67.7% received NAC prior to RC. Patients who received NAC were more likely to have cT3 disease, preoperative hydronephrosis, and variant histology on transurethral resection (p <0.001, p=0.004, p=0.029, respectively). Rates of recurrence or metastasis were similar between groups (27.0% vs 26.7%, p=0.964). No patients had isolated genitourinary organ recurrence (median followup 32.1 months). Nine patients (5.7%) had gynecologic organ involvement (6 NAC vs 3 no NAC, p=0.978). Among those who underwent hysterectomy, 2 patients (3.1%) who received NAC had uterine involvement compared to none in the no NAC cohort (p=0.551). Rates of vaginal involvement were similar between the groups (4 NAC vs 3 no NAC, p=0.402). Additionally, 1 patient who received NAC had incidentally diagnosed localized endometrial cancer. No women had fallopian tube or ovarian involvement. CONCLUSIONS: Even among high risk patients with MIBC, gynecologic organ involvement of MIBC is rare, and organ preservation, especially of the ovaries, is likely safe.
引用
- Bree KK, Hensley PJ, Westerman ME, et al. Contemporary Rates of Gynecologic Organ Involvement in Females with Muscle Invasive Bladder Cancer: A Retrospective Review of Women Undergoing Radical Cystectomy following Neoadjuvant Chemotherapy. J Urol. 2021. PMID: 33872050. doi:10.1097/JU.0000000000001784
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。